GenMar Pharma GmbH is a manufacturer of a biological API used in the production of drug products for the treatment of respiratory distress syndrome (RDS) in premature babies. GenMar was founded in 2023 by Lyomark Pharma GmbH and Aerogen Pharma.
Currently, GenMar is in the structuring and build-up phase. In addition to establishing the organizational framework, two new state-of-the-art manufacturing facilities are being built in Buchloe and Kaufbeuren to ensure the future supply of this life-saving API.
Company Details
- Employees
- 11
- Founded
- 2023
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Keywords
- de l’industrie pharmaceutique !.
Genmar Pharma Gmbh Questions
Genmar Pharma Gmbh's LinkedIn profile is https://www.linkedin.com/company/genmar-pharma-gmbh
Genmar Pharma Gmbh has
11 employees.
View email and phone details for 11
employees at Genmar Pharma Gmbh.
Genmar Pharma Gmbh's industry is
Pharmaceutical Manufacturing
Genmar Pharma Gmbh's top competitors are
Bendalis Gmbh,
Gemoab Gmbh,
Itf Pharma Gmbh,
Lyomark Pharma Gmbh,
Cellex Cell Professionals,
Aerogen Pharma,
Helmholtz Centre For Environmental Research (Ufz),
Synlab Holding Deutschland Gmbh,
Raaven Therapeutics,
Kyberg Pharma Vertriebs-Gmbh.
Genmar Pharma Gmbh's categories are Pharmaceutical Manufacturing
Genmar Pharma Gmbh's founding year is 2023
